Skip to content

Released Aug 10, 2021, before the open

10-Q filed Aug 10, 2021, 41 days after period end · 0001628280-21-016418

Q2 2021 · 10-Q
Revenue$279.00K— vs Q2 2020−2.4% vs Q1 2021
Net Income-$23.11MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.63N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$23,261,000N/M
Operating Cash Flowderived-$18,483,000N/M
Free Cash Flowderived-$19,692,000N/M
Margins · derived
Operating margin-8337.3%
Net margin-8283.5%

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020
Revenue$279.00K$0.00
Net Income-$23.11M-$15.72M
EPS Diluted-$0.63-$2.90

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR